CD47抑制剂在恶性肿瘤治疗中研究进展  

Research progress of CD47 inhibitors in malignant tumor treatment

作　　者：胡杰轩 张颖[1] 陈培士 赵宏[1] 苏强[1] HU Jie-xuan;ZHANG Ying;CHEN Pei-shi;ZHAO Hong;SU Qiang(Department of Cancer Center,Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing 100050,China;Department of Oncology,Guanxian People's Hospital of Liaocheng City,Liaochehg 252500,China)

机构地区：[1]首都医科大学附属北京友谊医院肿瘤中心,北京100050 [2]冠县人民医院肿瘤内科,山东冠县252500

出　　处：《中华肿瘤防治杂志》2021年第6期478-482,共5页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金重大研究计划培育项目(92046015);北京市自然科学基金项目、北京市教育委员会科技发展计划重点项目(KZ-202010025047)。

摘　　要：目的针对淋巴瘤和恶性实体肿瘤,多项以CD47为靶点单克隆抗体的Ⅰ-Ⅱ期临床试验已经展开,本研究对CD47抑制剂在多种恶性肿瘤临床应用中的研究进展进行综述。方法应用PubMed及CNKI期刊全文数据库检索系统,以"CD47、巨噬细胞、免疫治疗、恶性肿瘤"为关键词,检索2009-01-2018-12的相关文献,共检索到英文文献795条,中文文献205条。纳入标准:CD47抑制剂在血液肿瘤及实体瘤中的临床试验研究;CD47及CD47抑制剂的相关机制研究。剔除标准:与CD47及CD47抑制剂不相关;临床试验结果相似或者重复;机制阐述不清楚。符合纳入标准的中文文献20条,英文文献43条,根据剔除标准剔除中文文献16条,英文文献25条,最后纳入分析22篇文献。结果实验结果已经证实CD47在多种恶性肿瘤中呈高表达。目前的临床试验数据显示CD47抑制剂在抗肿瘤疗效及安全性上显示出较好的结果。结论CD47抑制剂通过激活巨噬细胞对肿瘤细胞的吞噬显示了抗肿瘤作用,是很有潜力的肿瘤免疫治疗新靶点。但在具体的疗效、最佳剂量、安全性以及用药方式等方面还需要更多的临床试验来探索。Objective This paper reviews the progress of the clinical application of CD47 inhibitors in a variety of malignant tumors.Methods PubMed and CNKI journal full-text database retrieval system were used to retrieve relevant literatures from January 2009 to December 2018,with"CD47,macrophages,immunotherapy,malignant tumors"as keywords.A total of 795 literatures in English and 205 literatures in Chinese were retrieved.Inclusion criteria:clinical trials of CD47 inhibitors in hematologic tumors and solid tumors;study on related mechanisms of CD47 and CD47 inhibitors.Elimination criteria:not associated with CD47 and CD47 inhibitors;similar or duplicate clinical trial results;the mechanism is not clearly explained.There were 20 literatures in Chinese and 43 literatures in English that met the inclusion criteria.According to the exclusion criteria,16 literatures in Chinese and 25 literatures in English were excluded.Finally,22 literatures were included in the analysis.Results The experimental results have confirmed that CD47 was highly expressed in a variety of malignant tumors.Current clinical trial data showed that CD47 inhibitors had shown good results in terms of anti-tumor efficacy and safety.Conclusion CD47 inhibitors shows anti-tumor effect by activating macrophages to phagocytosis of tumor cells,which is a potential new target of tumor immunotherapy.However,more clinical trials are needed to explore the specific efficacy,optimal dosage,safety and medication methods.

关 键 词：CD47 巨噬细胞 免疫治疗 恶性肿瘤 

分 类 号：R730.3[医药卫生—肿瘤]